JP2015510894A5 - - Google Patents

Download PDF

Info

Publication number
JP2015510894A5
JP2015510894A5 JP2015500618A JP2015500618A JP2015510894A5 JP 2015510894 A5 JP2015510894 A5 JP 2015510894A5 JP 2015500618 A JP2015500618 A JP 2015500618A JP 2015500618 A JP2015500618 A JP 2015500618A JP 2015510894 A5 JP2015510894 A5 JP 2015510894A5
Authority
JP
Japan
Prior art keywords
heterocyclyl
alkyl
heteroaryl
aryl
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015500618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510894A (ja
JP6120941B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/031464 external-priority patent/WO2013138613A1/en
Publication of JP2015510894A publication Critical patent/JP2015510894A/ja
Publication of JP2015510894A5 publication Critical patent/JP2015510894A5/ja
Application granted granted Critical
Publication of JP6120941B2 publication Critical patent/JP6120941B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015500618A 2012-03-16 2013-03-14 ３，５−ジアミノピラゾールキナーゼ阻害剤 Active JP6120941B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612007P 2012-03-16 2012-03-16
US61/612,007 2012-03-16
PCT/US2013/031464 WO2013138613A1 (en) 2012-03-16 2013-03-14 3,5-diaminopyrazole kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2015510894A JP2015510894A (ja) 2015-04-13
JP2015510894A5 true JP2015510894A5 (enExample) 2016-05-12
JP6120941B2 JP6120941B2 (ja) 2017-04-26

Family

ID=47997976

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015500618A Active JP6120941B2 (ja) 2012-03-16 2013-03-14 ３，５−ジアミノピラゾールキナーゼ阻害剤
JP2015500620A Expired - Fee Related JP6134376B2 (ja) 2012-03-16 2013-03-14 ３，５−ジアミノピラゾールキナーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015500620A Expired - Fee Related JP6134376B2 (ja) 2012-03-16 2013-03-14 ３，５−ジアミノピラゾールキナーゼ阻害剤

Country Status (18)

Country Link
US (4) US8916555B2 (enExample)
EP (2) EP2834232A1 (enExample)
JP (2) JP6120941B2 (enExample)
KR (1) KR20140138293A (enExample)
CN (2) CN104302640A (enExample)
AR (1) AR092809A1 (enExample)
AU (2) AU2013205306B2 (enExample)
CA (2) CA2867469A1 (enExample)
HK (2) HK1207072A1 (enExample)
IL (1) IL234654A0 (enExample)
MX (1) MX2014011115A (enExample)
NZ (2) NZ628080A (enExample)
PH (1) PH12014502056A1 (enExample)
RU (1) RU2014141674A (enExample)
SG (2) SG11201405761WA (enExample)
TW (1) TW201341367A (enExample)
WO (2) WO2013138613A1 (enExample)
ZA (1) ZA201406777B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302640A (zh) * 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
US11693383B1 (en) 2013-05-31 2023-07-04 Signify Holding B.V. Systems and methods for providing hub-based motion detection using distributed, light-based motion sensors
US10585004B1 (en) 2015-07-15 2020-03-10 Signify North America Corporation Systems and methods for determining ambient temperature using lighting based sensors
US10285243B2 (en) 2013-05-31 2019-05-07 Signify North America Corporation Systems and methods for providing a self-adjusting light source
NZ631142A (en) * 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3140298A1 (en) 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
EP3147283B1 (en) 2014-05-22 2022-08-17 North China Pharmaceutical Company., Ltd. Hydrazine compound as blood coagulation factor xa inhibitor
US9726537B2 (en) 2014-10-31 2017-08-08 Stack Labs, Inc. Systems and methods for determining ambient illumination having a bypass switch
MY191736A (en) * 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
CN104910075B (zh) * 2015-06-23 2017-04-12 安徽农业大学 一种双吡唑希夫碱化合物及其制备方法及其作为杀菌剂的应用
US9642216B1 (en) 2015-08-11 2017-05-02 Stack Labs, Inc. Systems and methods for synchronizing lighting devices
US10512138B1 (en) 2015-09-15 2019-12-17 Signify North America Corporation Systems and methods for self learning ambient light sensors
CN105418616B (zh) * 2015-12-26 2018-01-12 山东大学 一种含有 4‑氨基吡唑结构的jak 激酶抑制剂及其制备方法和应用
CA3186668A1 (en) * 2020-07-20 2022-01-27 Neurodon Corporation Quinolines that modulate serca and their use for treating disease
EP4637753A2 (en) * 2022-12-23 2025-10-29 Acrivon Therapeutics, Inc. Phenyl-pyrazole carboxamide compounds

Family Cites Families (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
JPH072743B2 (ja) 1988-10-21 1995-01-18 富士写真フイルム株式会社 １Ｈ−ピラゾロ〔５，１−ｃ〕−１，２，４−トリアゾール類およびピラゾール誘導体の製造方法
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
HU219131B (hu) 1991-10-18 2001-02-28 Monsanto Co. Módszer és fungicid készítmény növények torsgombabetegségének gátlására és a hatóanyagok
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
HRP921338B1 (en) 1992-10-02 2002-04-30 Monsanto Co Fungicides for the control of take-all disease of plants
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
DE4405207A1 (de) 1994-02-18 1995-08-24 Bayer Ag N-Pyrazolylaniline und N-Pyrazolylaminopyridine
US5958458A (en) 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
JP3056788B2 (ja) 1994-06-24 2000-06-26 ユーロ−セルティーク，エス．エイ． ホスホジエステラーゼｉｖの阻害化合物および阻害方法
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
AU1735497A (en) 1996-02-26 1997-09-10 Sumitomo Pharmaceuticals Company, Limited Sulfonylureidopyrazole derivatives
US5959109A (en) 1996-05-15 1999-09-28 Neurocrine Biosciences, Inc. Compounds and methods for increasing endogenous levels of corticotropin-releasing factor
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
US6375987B1 (en) 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
DE19648576C2 (de) 1996-11-23 1999-08-12 Lohmann Therapie Syst Lts Lutschtablette zur modifizierten Freisetzung von Wirkstoffen im Gastrointestinaltrakt
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US7169410B1 (en) 1998-05-19 2007-01-30 Sdg, Inc. Targeted liposomal drug delivery system
IL142896A0 (en) 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
HN2000000051A (es) 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
ATE267830T1 (de) 1999-08-27 2004-06-15 Abbott Lab Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
US6472416B1 (en) 1999-08-27 2002-10-29 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors
CA2387892A1 (en) 1999-10-18 2001-04-26 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US8084467B2 (en) 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
WO2001064669A1 (en) 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
US6623756B1 (en) 2000-04-27 2003-09-23 Noveon Ip Holdings Corp. Directly compressed solid dosage articles
CA2420535A1 (en) 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
AU2001290912A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6464767B1 (en) 2000-10-12 2002-10-15 Eastman Kodak Company Ink jet printing method
US6468338B1 (en) 2000-10-12 2002-10-22 Eastman Kodak Company Dye for ink jet ink
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
WO2002053160A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating glaucoma ivb
DE10108480A1 (de) 2001-02-22 2002-09-05 Bayer Ag Pyrazolylpyrimidine
US6770645B2 (en) 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
GB0106661D0 (en) 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
US6593349B2 (en) 2001-03-19 2003-07-15 Icagen, Inc. Bisarylamines as potassium channel openers
JP2002309137A (ja) 2001-04-12 2002-10-23 Fuji Photo Film Co Ltd インクジェット記録用インク組成物
KR20100008794A (ko) 2001-04-16 2010-01-26 쉐링 코포레이션 Ｃｘｃ-케모카인 수용체 리간드로서의 3,4-이치환된 사이클로부텐-1,2-디온
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
WO2002096905A1 (en) 2001-06-01 2002-12-05 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinases
CN1473035B (zh) 2001-07-27 2012-07-18 安斯泰来制药有限公司 含有口腔内迅速崩解片剂用缓释微粒的组合物及其制造方法
JP2005507875A (ja) 2001-08-31 2005-03-24 ユニバーシティ オブ コネチカット カンナビノイド受容体に作用する新規なピラゾール類似体
MXPA04002973A (es) 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosis de liberacion modificada.
JP2005505595A (ja) 2001-10-12 2005-02-24 シェーリング　コーポレイション Ｃｘｃ−ケモカインレセプターアンタゴニストとしての３，４−二置換マレイミド化合物
AU2002363250A1 (en) 2001-11-01 2003-05-12 Icagen, Inc. Pyrazole-amides and-sulfonamides
WO2003037336A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
WO2003037335A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 5-heteroatom-substituted pyrazoles
DK1355633T3 (da) 2001-12-19 2005-04-04 Astrazeneca Ab Ny filmcoating, der indeholder en ethylacrylat/methylmethacrylat-copolymer og polyvinylacetat
ATE446093T1 (de) 2001-12-24 2009-11-15 Astrazeneca Ab Substituierte chinazolin-derivate als aurora- kinase inhibitoren
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
US20040024085A1 (en) 2002-01-30 2004-02-05 Takahiro Ishizuka Ink composition and inkjet recording method
WO2003073989A2 (en) 2002-02-28 2003-09-12 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
US6958161B2 (en) 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
US20040029887A1 (en) 2002-05-23 2004-02-12 Bhatia Pramila A. Acetamides and benzamides that are useful in treating sexual dysfunction
US20030232836A1 (en) 2002-05-23 2003-12-18 Stewart Andrew O. Acetamides and benzamides that are useful in treating sexual dysfunction
WO2003099266A2 (en) 2002-05-23 2003-12-04 Abbott Laboratories Acetamides and benzamides that are useful in treating sexual dysfunction
US20060009461A1 (en) 2002-05-23 2006-01-12 Bhatia Pramila A Acetamides and benzamides that are useful in treating sexual dysfunction
US6989451B2 (en) 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
AU2003295041A1 (en) 2002-11-20 2004-06-18 L'oreal Composition for hair care or eyelashes containing a pyrazol-carboxamide, its use for stimulating hair and eyelash growth and/or for preventing loss thereof
FR2847160A1 (fr) 2002-11-20 2004-05-21 Oreal Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute
US7485322B2 (en) 2002-12-24 2009-02-03 Lek Pharmaceuticals D.D. Modified release pharmaceutical composition
JP2004238296A (ja) * 2003-02-04 2004-08-26 Kissei Pharmaceut Co Ltd 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
US20060270628A1 (en) 2003-04-29 2006-11-30 Jagattaran Das Antiinfective 1,2,3-triazole derivatives, process for their preparation and pharmaceutical compositions containing them
CN101152185B (zh) 2003-06-06 2010-12-08 阿里克斯股份公司 杂环化合物作为scce抑制剂的用途
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
WO2005001083A1 (en) 2003-06-27 2005-01-06 Actimis Pharmaceuticals, Inc. Regulation of kinase, ´regulated in copd kinase´ (rc kinase)
NZ545132A (en) 2003-07-08 2009-07-31 Astrazeneca Ab Spiro[1-azabicyclo[2.2.2.]octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor
GB0319793D0 (en) 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
CN1926139A (zh) 2004-02-27 2007-03-07 霍夫曼-拉罗奇有限公司 稠合吡唑衍生物
KR100844864B1 (ko) 2004-02-27 2008-07-09 에프. 호프만-라 로슈 아게 헤테로아릴-융합 피라졸로 유도체
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
AU2005225471B2 (en) 2004-03-26 2011-05-12 Methylgene Inc. Inhibitors of histone deacetylase
JP4790703B2 (ja) 2004-04-07 2011-10-12 武田薬品工業株式会社 環式化合物
US7033425B2 (en) 2004-04-15 2006-04-25 Eastman Kodak Company Ink jet ink set
EP1742921A2 (en) 2004-04-21 2007-01-17 AstraZeneca AB Pyrazole derivatives useful for the treatment of cancer
US7399317B2 (en) 2004-08-26 2008-07-15 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
CA2577937C (en) 2004-08-26 2010-12-21 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
US7662482B2 (en) 2004-09-01 2010-02-16 Dow Global Technologies, Inc. Adhesion promoter
US7531560B2 (en) 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
MX2007005857A (es) 2004-11-17 2007-10-10 Mikana Therapeutics Inc Inhibidores de cinasa.
DK2383268T3 (en) 2005-02-04 2015-09-14 Astrazeneca Ab PYRAZOLYLAMINOPYRIDINDERIVATER useful as kinase inhibitors
KR20070104936A (ko) 2005-02-16 2007-10-29 아스트라제네카 아베 화합물
KR101362621B1 (ko) 2005-02-16 2014-02-13 아스트라제네카 아베 화합물
US20090053455A1 (en) 2005-03-29 2009-02-26 Mitsubishi Kagaku Media Co., Ltd Optical recording medium, metal complex compound and organic dye compound
CA2603457A1 (en) * 2005-04-07 2006-10-19 Teijin Pharma Limited Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
JP2008540335A (ja) 2005-04-27 2008-11-20 アストラゼネカ・アクチエボラーグ ピラゾリル・ピリミジン誘導体の疼痛治療における使用
JP2008540391A (ja) 2005-05-05 2008-11-20 アストラゼネカ アクチボラグ ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用
WO2007002764A2 (en) 2005-06-29 2007-01-04 Schering Corporation Di-substituted oxadiazoles as cxc-chemokine receptor ligands
US7737151B2 (en) 2005-08-18 2010-06-15 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
JP2007056213A (ja) 2005-08-26 2007-03-08 Fujifilm Corp 焼結含油軸受油用組成物、並びにそれを用いた軸受け装置及び摺動部材
JP5249770B2 (ja) 2005-11-03 2013-07-31 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリジン
ATE508126T1 (de) 2005-11-16 2011-05-15 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
US7728017B2 (en) 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
WO2007084868A2 (en) 2006-01-17 2007-07-26 Kalypsys, Inc. Treatment of disorders by activation of the unfolded protein response
US7427414B2 (en) 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
GB0605691D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
MX2009002299A (es) 2006-09-01 2009-03-20 Cv Therapeutics Inc Metodos y composiciones para incrementar la tolerancia del paciente durante metodos de formacion de imagenes del miocardio.
US20090081120A1 (en) 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
JP2010502706A (ja) 2006-09-07 2010-01-28 ミレニアム・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害活性を有するフェネチルアミド誘導体
US20090062273A1 (en) 2006-12-15 2009-03-05 Ingo Hartung 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same.
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
US7947698B2 (en) 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2008128968A1 (en) 2007-04-19 2008-10-30 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5
JP2010529193A (ja) 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
WO2009032703A1 (en) 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
KR20100090250A (ko) 2007-10-09 2010-08-13 메르크 파텐트 게엠베하 글루코키나제 활성체로서 유용한 피리딘 유도체
US20100292447A1 (en) 2007-10-12 2010-11-18 Merck Patent Gesellschaft Method and agent for refolding proteins
SG185996A1 (en) 2007-11-13 2012-12-28 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
US20090143451A1 (en) 2007-11-14 2009-06-04 Andrews William H Compounds that increase telomerase reverse transcriptase (tert) expression and methods for using the same
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
CA2716599A1 (en) 2008-02-25 2009-09-03 Lars Thore Burgdorf Glucokinase activators
JP5117885B2 (ja) 2008-02-29 2013-01-16 富士フイルム株式会社 色素化合物、着色組成物、感熱転写記録用インクシート、感熱転写記録方法、カラートナー、インクジェット用インクおよびカラーフィルター
EP2265592A1 (en) 2008-03-14 2010-12-29 Basf Se Substituted pyraz inylmethyl sulfonamides for use as. fungicides
JP2009235122A (ja) 2008-03-25 2009-10-15 Fujifilm Corp インク組成物、インクセット、及び画像記録方法
EP2276746A1 (en) 2008-04-10 2011-01-26 Basf Se Substituted pyridazinylmethyl sulfonamides
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
UA105005C2 (uk) 2008-06-16 2014-04-10 Юніверсіті Оф Теннессі Рісерч Фаундейшн Сполуки для лікування раку
CN102124000B (zh) 2008-06-17 2014-09-17 阿斯利康(瑞典)有限公司 吡啶化合物
LT2318006T (lt) 2008-08-15 2017-01-10 Nivalis Therapeutics, Inc. Nauji s-nitrozoglutationo reduktazės pirolo inhibitoriai, kaip terapiniai agentai
EA022417B1 (ru) 2008-10-21 2015-12-30 Саймабэй Терапевтикс, Инк. Арильные агонисты рецептора gpr120 и их применение
WO2010048559A2 (en) 2008-10-24 2010-04-29 Calcimedica Inc. Phenylpyrazole inhibitors of store operated calcium release
EP2379684A2 (de) 2008-12-22 2011-10-26 Basf Se Mischungen hydrophober und hydrophiler ionischer flüssigkeiten und ihre verwendung in flüssigkeitsringverdichtern
MX2011008674A (es) 2009-02-18 2011-11-04 Amgen Inc Compuestos de indol/bencimidazol como inhibidores de quinasa mtor.
ES2761295T3 (es) 2009-03-02 2020-05-19 Stemsynergy Therapeutics Inc Métodos y composiciones para su uso en el tratamiento del cáncer y para reducir los efectos mediados por Wnt en una célula
FR2943057B1 (fr) 2009-03-12 2011-06-03 Centre Nat Rech Scient DERIVES DE 10-AMINO-1,2,3,4-TETRAHYDROPYRIDO°2,1-a!ISOINDOL-6(10bH)- ONES, LEUR PROCEDE DE PREPARATION ET LEURS UTILISATIONS THERAPEUTIQUES
JP2012520887A (ja) 2009-03-18 2012-09-10 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物
US20100240720A1 (en) 2009-03-20 2010-09-23 Burnham Institute For Medical Research Allosteric jnk inhibitors
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
CN102458402B (zh) * 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
WO2011056895A1 (en) 2009-11-03 2011-05-12 University Of Notre Dame Du Lac Ionic liquids comprising heteraromatic anions
CA2791738C (en) 2010-03-01 2020-06-09 Gtx, Inc. Aryl imidazolyl compounds for the treatment of cancer
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
WO2012154880A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2015510895A5 (enExample)
RU2014141674A (ru) 3,5-диаминопиразоловые ингибиторы киназы
JP2017510643A5 (enExample)
ES2533065T3 (es) Bencenosulfonamidas útiles como inhibidores de los canales de sodio
JP2017510642A5 (enExample)
JP2017510644A5 (enExample)
JP2013526538A5 (enExample)
JP2013526541A5 (enExample)
JP2014509647A5 (enExample)
JP2013522316A5 (enExample)
JP2015511638A5 (enExample)
WO2012122340A1 (en) Soluble guanylate cyclase activators
JP2012512906A5 (enExample)
JP2017525737A5 (enExample)
EP2400962A1 (de) Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
JP2016522246A5 (enExample)
JP2016525078A5 (enExample)
JP2013529199A5 (enExample)
CA2718383A1 (en) Heteroaryl-substituted dicyanopyridines and use thereof for treatment of cardiovascular diseases
JP2013526539A5 (enExample)
JP2016513661A5 (enExample)
CN105085428B (zh) 芳杂环类衍生物及其在药物上的应用
CN110770233A (zh) 稠合双环类化合物及其在药物中的应用
JP2005534623A (ja) Ｅｒｂファミリーの阻害剤並びにｒａｆ及び／又はｒａｓ阻害剤を投与することを含む癌の治療法
JP2015536986A (ja) 併用療法